By: Christine Klimanskis, Justin Cooper
PHOENIX — Mirvetuximab, an antibody drug conjugate for the treatment of certain types of cancer, can lead to adverse ocular events in the early weeks of treatment, according to a poster here.
Christine Klimanskis is a Copy Chief at Healio, where she leads a skilled team of copy editors in ensuring high-quality medical journalism. With a focus on medicine and healthcare, her work encompasses various topics including consumer health, patient care, and digital health, particularly within the realm of ophthalmology. Klimanskis has been featured in the World Wealth Journal and Healio, highlighting her expertise in the medical publishing field.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston


Not enough data
Christine Klimanskis' articles predominantly focus on ophthalmology, eye diseases, medical technology, and surgical procedures. Her coverage frequently cites data and incorporates expert commentary.
Given her emphasis on scientific research and healthcare advancements in ophthalmology, Christine may be interested in pitches from professionals who can provide substantive insights into new diagnostic tools or emerging treatments for eye diseases. Sources with expertise in ophthalmic research or clinical practice management could offer valuable contributions to her work.
As she does not have a specific geographic focus, experts from various regions who are at the forefront of innovative developments in ophthalmology and related fields may find success when reaching out to her.
This information evolves through artificial intelligence and human feedback. Improve this profile .